当前位置: X-MOL 学术Antivir. Ther. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study.
Antiviral Therapy ( IF 1.3 ) Pub Date : 2017-04-12 , DOI: 10.3851/imp3166
Benoît Trottier 1 , Jordan E Lake 2 , Ken Logue 3 , Cynthia Brinson 4 , Lizette Santiago 5 , Clare Brennan 6 , Justin A Koteff 6 , Brian Wynne 7 , Judy Hopking 8 , Catherine Granier 8 , Michael Aboud 9
Affiliation  

Simplified dosing regimens are important for patients who face challenges in adhering to HIV-1 therapy. We investigated the safety and virological efficacy of switching to once-daily abacavir/dolutegravir/lamivudine (ABC/DTG/3TC).

中文翻译:

在病毒抑制患者中,Dolutegravir / abacavir / lamivudine与目前的ART相比(STRIIVING):一项为期48周的随机,非劣效,开放标签的IIIb期研究。

对于在坚持HIV-1治疗方面面临挑战的患者,简化给药方案非常重要。我们调查了每天换用阿巴卡韦/杜鲁格韦/拉米夫定(ABC / DTG / 3TC)的安全性和病毒学功效。
更新日期:2020-08-21
down
wechat
bug